3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
32
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Leukemia
16
Lymphoma, Non-Hodgkin
9
Lymphoma
9
Leukemia, Lymphocytic, Chronic, B-Cell
8
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma, Mantle-Cell
6
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma, Follicular
5
Burkitt Lymphoma
5
Recurrence
4
Neoplasms
4
Myelodysplastic Syndromes
4
Lymphoma, Large-Cell, Anaplastic
4
Congenital Abnormalities
4
Anemia, Refractory, with Excess of Blasts
4
Waldenstrom Macroglobulinemia
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Myeloproliferative Disorders
3
Multiple Myeloma
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Extranodal NK-T-Cell
3
Leukemia, Myelomonocytic, Juvenile
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Immunoblastic Lymphadenopathy
3
Hematologic Neoplasms
3
Thrombocythemia, Essential
2
Sezary Syndrome
2
Primary Myelofibrosis
2
Interventions
posaconazole
4
Caspofungin
4
Voriconazole
3
Fluconazole
3
Standard of Care
2
liposomal amphotericin B
1
Levofloxacin
1
Itraconazole
1
Drug Therapy
1
Amphotericin B
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mycoses
×
Drug Therapy
×
Other hematologic neoplasm
×
Clear all
NCT03301597
2021-03-30
LAUNCH
Nohla Therapeutics, Inc.
Phase 2
Terminated
146 enrolled